Deutsch | English | по-русски | Türkçe 

Molecular Pathogenesis and Progression of Lymphoproliferative Disorders

Contact/Address

Prof. Dr. Stephan Stilgenbauer


Department of Internal Medicine III
Ulm University
Albert-Einstein-Allee 23
89081 Ulm
Germany


E-Mail: stephan.stilgenbauer[at]uniklinik-ulm.de

Phone (direct):
Phone (study office):
Fax:

0049+(0)731-500-45521
0049+(0)731-500-45901
0049+(0)731-500-45925

 

Project Leader

Prof. Dr. Stephan Stilgenbauer

 

Scientific Lab Members

Dr. Johannes Bloehdorn
Dr. Jennifer Edelmann
Dr. Sven Estenfelder
Sonia Jaramillo
Dr. Billy Jebaraj
Veronika Opatrna
Dr. rer. nat. Annika Scheffold
Dipl. Biol. Daniela Steinbrecher
Dr. Eugen Tausch

Technicians

Jacqueline Fiegel
Melanie Flauger
Christina Galler
Linda Janetti
Marjana Jovanovic
Sarah Keller
Eva Moll
Melinda Oechsle
Sabrina Rau
Julia Ritter
Sabrina Schrell

Research Fields

(A)

Incidence of genomic aberrations of CLL and mantle cell lymphoma (MCL). Analysis by fluorescence in-situ hybridization (FISH) with comprehensive probe sets for +(3q26), del(6q21), +(8q24), del(11q22-23), +(12q13), del(13q14), t(11;14)(q13;q32), t(14;18)(q32;q21), t(14q32), del(17p13) in CLL and in addition for del(1p22), del(6q27), +(7p15), del(8p22), del(9p21), del(10p15), +(15q23), del(18p11), +(Xq28) in MCL. Development of automated high-resolution genotyping through microarray based matrix-CGH and SNP-chip analyses.

(B)

Characterization of critical regions and isolation of candidate genes involved in pathogenesis and clinical progression. For the most frequently involved genomic regions such as del(1p22), +(3q26), del(6q21), del(8p22), +(8q24), del(11q22-23), +(12q13), and del(13q14) the affected genes are mostly unknown. The critical regions are defined and candidate genes are isolated and subjected to expression as well as mutation analyses.

(C)

Identification of VDJ rearrangement and IGHV mutation status in lymphoproliferative disorders. Amplification of VDJ rearrangements from RNA and DNA by GeneScan technology based multiplex PCR and sequencing of the products. Characterization of VDJ structure, VH gene usage and mutation status in various B-cell malignancies to define their role in pathogenesis and clinical course of the disease.

(D)

Gene expression profiling of lymphoproliferative disorders. Deregulation of gene expression (mRNA and miR) is studied through microarray and TaqMan approaches in relation to disease subgroups defined by molecular and clinical markers. Changes in gene expression are studied during disease evolution and under specific treatments. Protein expression of candidate genes, in particular of cell cycle, apoptosis control are studied by Western blot analysis.

(E)

Expression analysis of surrogate markers of pathogenic and prognostic significance in CLL such as ZAP-70, SEP-10, LPL, etc. by flow cytometry, TaqMan, and Western blotting. Technical development and validation of the different markers in well characterized cohorts of patients.

 

(F)

Mutation profiling of lymphoproliferative disorders. Mutations of different genes (e.g. TP53, ATM, MDM2, etc.) involved in the pathogenesis are studied by DHPLC (Denaturing High Performance Liquid Chromatography) and direct sequencing. The results are analysed in relation to disease subgroups defined by molecular and clinical markers. The consequences of gene mutations are characterised by the analysis of changes or signatures in gene expression, protein expression and functional assays after irradiation or chemotherapy.

 

(G)

Genomics analyses by next generation sequencing technologies (whole exome, whole genome, RNAseq, etc.) by Illumina Hiseq and targeted resequencing by Illumina MiSeq technology. Identification of pathogenic mechanisms in the development and progression of malignancies as well as in clonal evolution and treatment resistance. Subgroup definition for personalized treatment in a “precision medicine” approach.

(H)

Model systems for pathogenesis and resistance mechanisms in lymphoid malignancies. Cell lines and co-culture approaches including manipulation and interference (shRNA, lentiviral infection, CRISPR technology). Mouse models involving adoptive transfer and transplantation studies as well as generation of new transgenic animals.

 

 

(I)

Central genetics reference laboratory of the German CLL Study Group (GCLLSG) focused on characterization of genomic aberrations, mutations, gene expression, cell cycle/apoptosis and tumor bank. Development of databases and compilation of datasets for comprehensive biologic and clinical characterization of leukemia and lymphoma. Identification of molecular risk markers predicting progression, treatment response, and survival. Development and coordination of clinical trial protocols based on molecular risk-assessment with innovative treatment approaches (risk stratification, resistance mechanisms, small molecules, antibody therapy, stem cell transplantation)

 

 

Techniques

  • Isolation of tumor cells by ficoll gradient and immunomagnetic cell sorting
  • fluorescence in-situ hybridization (FISH), also in combination with immunostaining
  • DNA and RNA preparation of cells and tissues
  • PCR and RT-PCR techniques, (including multiplex and TaqMan analyses)
  • DNA sequencing, sequence analysis cloning and preparation of various vector systems (plasmids, cosmids, BAC, PAC, YAC)
  • microarray expression (mRNA and miR) and genomic profiling (SNP chip).
  • Flow cytometry (FACS) of diverse intracellular antigens (ZAP-70 etc.)
  • Sensitive mutation profiling of different genes (e.g. TP53, ATM, MDM2, etc.) by DHPLC (WAVE)
  • Next generation sequencing techniques (targeted and whole exome / whole genome) by Illumina MiSeq and Illumina HiSeq technology
  • Mouse models (transplantation and transgenic)

Grants/Funding

  • DFG
  • Deutsche Krebshilfe
  • Deutsche José Carreras Leukämie-Stiftung
  • Else Kröner-Fresenius Stiftung
  • Wilhelm Sander Stiftung
  • Land Baden-Württemberg, Bundesministerium für Bildung und Forschung,
  • Europäische Kommissio
  • Helmholtz Gemeinschaft
  • CLL Global Research Foundation
  • Industrie, etc.

Representative Publications

Oakes CC, Seifert M, Assenov Y, Gu L, Przekopowitz M, Ruppert AS, Wang Q, Imbusch CD, Serva A, Koser SD, Brocks D, Lipka DB, Bogatyrova O, Weichenhan D, Brors B, Rassenti L, Kipps TJ, Mertens D, Zapatka M, Lichter P, Döhner H, Küppers R, Zenz T, Stilgenbauer S, Byrd JC, Plass C. DNA methylation dynamics during B cell maturation underlie a continuum of disease phenotypes in chronic lymphocytic leukemia.

Nature Genet. 48(3):253-64, 2016.

 

Stilgenbauer S, Eichhorst B,  Schetelig J, Coutre S, Seymour JF, Munir T , Puvvada SD, Wendtner CM, Roberts AW, Jurczak W, Mulligan SP, Böttcher S, Mobasher M, Zhu M, Desai M, Chyla B, Verdugo M, Heitner Enschede S, Cerri E, Humerickhouse R, Gordon G, Hallek M, Wierda WG. Venetoclax in Relapsed or Refractory Chronic Lymphocytic Leukemia with 17p Deletion: a Phase 2, Open Label, Multicenter Study.
Lancet Oncology
17(6):768-78.2016, 2016.

 

Landau DA*, Tausch E* Taylor-Weiner AN*, Stewart, C, Reiter JG, Bahlo J, Kluth S, Bozic I, Lawrence M, Böttcher S, Cibulskis K, Mertens D, Sougnez C, Rosenberg M, Hess JM, Carter SL, Edelmann J, Kless S, Fink A, Fischer K, Gabriel S, Lander E, Nowak MA, Döhner H, Hallek M*, Neuberg D*, Getz G*, Stilgenbauer S*, Wu CJ*. Somatic mutations driving chronic lymphocytic leukemia and their evolution in disease progression and relapse.

Nature 526(7574):525-30, 2015. *Equal contribution

 

Stilgenbauer S, Schnaiter A, Paschka P, Zenz T, Rossi M, Döhner K, Bühler A, Böttcher S, Ritgen M, Kneba M, Winkler D, Tausch E, Hoth P, Edelmann J, Mertens D, Bullinger L, Bergmann M, Kless S, Mack S, Jäger U, Patten N, Wu L, Wenger MK, Fingerle-Rowson G, Lichter P, Cazzola M, Wendtner CM, Fink AM, Fischer K, Busch R, Hallek M, Döhner H:
Gene mutations and treatment outcome in chronic lymphocytic leukemia: results from the CLL8 trial.
Blood 123(21):3247-54, 2014
    
Woyach JA, Furman RR, Liu TM, Ozer HG, Zapatka M, Ruppert AS, Xue L, Li DH, Steggerda SM, Versele M, Dave SS, Zhang J, Yilmaz AS, Jaglowski SM, Blum KA, Lozanski A, Lozanski G, James DF, Barrientos JC, Lichter P, Stilgenbauer S, Buggy JJ, Chang BY, Johnson AJ, Byrd JC:
Resistance mechanisms for the Bruton's tyrosine kinase inhibitor ibrutinib.
N Engl J Med 370(24):2286-94, 2014

Dreger P, Schnaiter A, Zenz T, Böttcher S, Rossi M, Paschka P, Bühler A, Dietrich S, Busch R, Ritgen M, Bunjes D, Zeis M, Stadler M, Uharek L, Scheid C, Hegenbart U, Hallek M, Kneba M, Schmitz N, Döhner H, Stilgenbauer S:
TP53, SF3B1, and NOTCH1 mutations and outcome of allotransplantation for chronic lymphocytic leukemia: six-year follow-up of the GCLLSG CLL3X trial.
Blood 121(16):3284-8, 2013

Zenz T, Mertens D, Küppers R, Döhner H, Stilgenbauer S.
From pathogenesis to treatment of chronic lymphocytic leukaemia.
Nat Rev Cancer. 2010 Jan;10(1):37-50.

Stilgenbauer S, Zenz T, Winkler D, Bühler A, Schlenk RF, Groner S, Busch R, Hensel M, Dührsen U, Finke J, Dreger P, Jäger U, Lengfelder E, Hohloch K, Söling U, Schlag R, Kneba M, Hallek M, Döhner H; German Chronic Lymphocytic Leukemia Study Group.
Subcutaneous alemtuzumab in fludarabine-refractory chronic lymphocytic leukemia: clinical results and prognostic marker analyses from the CLL2H study of the German Chronic Lymphocytic Leukemia Study Group.
J Clin Oncol. 2009 Aug 20;27(24):3994-4001.

Roos G, Kröber A, Grabowski P, Kienle D, Bühler A, Döhner H, Rosenquist R, Stilgenbauer S.
Short telomeres are associated with genetic complexity, high-risk genomic aberrations, and short survival in chronic lymphocytic leukemia.
Blood. 2008 Feb 15;111(4):2246-52.

Kienle D, Katzenberger T, Ott G, Saupe D, Benner A, Kohlhammer H, Barth TF, Höller S, Kalla J, Rosenwald A, Müller-Hermelink HK, Möller P, Lichter P, Döhner H, Stilgenbauer S.
Quantitative gene expression deregulation in mantle-cell lymphoma: correlation with clinical and biologic factors.
J Clin Oncol. 2007 Jul 1;25(19):2770-7.

Collaborations (selection):

  • Prof. Dr. P. Lichter, DKFZ, Heidelberg: Molekulare Pathogenese, Progression und Resistenzmechanismen bei hämatologisch-onkologischen Erkrankungen
  • Prof. Dr. C. Plass, DKFZ, Heidelberg,: Epigenomik Analysen und funktionelle Charakterisierung von Kandidatengenen 
  • Dipl. Stat. A. Benner, Bioinformatik, DKFZ, Heidelberg: Bioinformatische Analysen komplexer biologischer und klinischer Datensätze
  • Prof. Dr. P. Möller, Pathologie, Ulm: Molekulare Pathogenese und Progression maligner hämatologischer Systemerkrankungen
  • Prof. Dr. P. Gierschik, Pharmakologie, Ulm: Pathogenese und Resistenzmechanismen gegen neue „targeted drugs“ bei lymphatischen Neoplasien
  • Prof. Dr. H. Jumaa, Immunologie, Ulm: Rezeptor Signaltransduktion und molekulare Mechanismen in Maus und Mensch Modellen
  • Prof. Dr. S. Fulda, Frankfurt: Apoptosedefekte und deren Nutzung als therapeutische Ziele  
  • Prof. Dr. K.L. Rudolph, Direktor, Leibniz Institut für Alterungsforschung, Jena: Tumorstammzellen, Telomere und Seneszenz
  • Prof. Dr. A. Rosenwald, Pathologie, Würzburg: Genetik, Genexpression und zelluläre Modelle bei Non-Hodgkin Lymphomen
  • Prof. Dr. med. P. Dreger, Innere Medizin V, Heidelberg: Weiterentwicklung der hämatopoetischen Stammzelltransplantation  
  • Prof. Dr. M. Hallek, Innere Medizin I, Köln: Übertragung laborwissenschaftlicher Konzepte zur Pathogenese und Prognoseabschätzung in klinische Therapiestudien 
  • Prof. Dr. med J. Schetelig, Medizinische Klinik I, Dresden: Allogene Stammzelltransplantation bei der CLL (EBMT, Dresdner Studien)
  • Prof. Dr. R. Rosenquist, Uppsala: Biologische und klinische Charakterisierung der CLL mit V3-21 Genbenutzung
  • Prof. Dr. U. Jäger, Wien: Kokultur, Microenvironment, Signaltransduktion und Genexpression bei der CL
  • Prof. Dr. F. Cymbalista, Paris: Biologie lymphatischer Neoplasien in Gewebe und Heterogenität in verschiedenen Manifestationen
  • Prof. Dr. J. Gribben, London: Molekulare und zelluläre Charakterisierung von Pathogenese und Resistenz der CLL in Modellen der Maus und Mensch
  • Prof. Dr. N. Chiorazzi, New-York: Pathogenetische Bedeutung des B-Zellrezeptors und der Signaltransduktion sowie Transplantationsmodelle
  • Prof. Dr. R. Dalla-Favera, New-York: Molekulare und funktionelle Untersuchung lymphatischer Neoplasien in Mausmodellen
  • Prof. Dr. C. Wu, Harvard Medical School und Broad Institute, Boston: Next Generation Sequencing und Tumor Heterogenität
  • Prof. Dr. G. Getz, Harvard Medical School und Broad Institute, Boston: Bioinformatik und Analyse komplexer Next Generation Sequencing Datensätze
  • Industriekooperationen: Abbott, Amgen, Bayer, Boehringer Ingelheim, Celgene, Gilead, Genzyme, GSK, Hoffmann-La Roche, Janssen, Mundipharma, Novartis, Sanofi-Aventis, Schering, Wyeth
  • SFB1074
  • Deutsche Krebshilfe "Molekulare Mechanismen bei malignen Lymphomen"
  • German CLL Study Group (GCLLSG)
  • European Leukemia Net (ELN)
  • European Mantle Cell Lymphoma Network
  • European Research Initiative on CLL (ERIC)

Forschungsbereiche

Molecular Genetics of Myeloid Leukemia
Prof. Dr. Konstanze Döhner / Prof. Dr. Lars Bullinger

Molecular Genetics of Myeloproliferative Disorders
Dr. Frank Stegelmann / Prof. Dr. Konstanze Döhner

Molecular Pathogenesis and Progression of Lymphoproliferative Disorders
Prof. Dr. Stephan Stilgenbauer

Mechanisms of Leukemogenesis
PD Dr. Daniel Mertens

Molecular Pathogenesis and Prognostic Markers in Monoclonal Gammopathies
PD Dr. Christian Langer

Tumor Immunology Group (TIG)
Prof. Dr. Jochen Greiner

Haemostaseology
PD Dr. Christian Langer
 

Molecular Hematopoiesis
Dr. Florian Kuchenbauer

 

Emmy Noether Research Group

Dr. Jan Krönke

gepunktete hellblaue Linie 176px breit
gepunktete blaue Linie 1000px breit